Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, pulmonary fibrosis, systemic sclerosis, and chronic liver disease, some of them in the late-stage development of the company’s strong innovation pipeline. The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance®, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market.

See the rest here:
Boehringer expands production site in Greece for new medicine